Sustained Improvements in Itch, Skin Pain, and Health-Related Quality of Life through 5 years of Treatment with Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Ixekizumab, an inhibitor of IL-17A, has been shown to have significant benefits on both skin clearance and improvement in the quality of life of patients with moderate-to-severe plaque psoriasis.
- In UNCOVER-1, the label dose of ixekizumab provided clinically meaningful improvement in itch, skin pain, and quality of life as early as week 12.
- These improvements in itch, skin pain, DLQI, PSAB, and SF-36 MCS and PCS were sustained through 5 years of treatment.
Presenting Author
Melinda Gooderham, MSc, MD, FRCPC
SKiN Centre for Dermatology
Queen's University
Probity Medical Research
Peterborough, Ontario, Canada
Melinda Gooderham is a Dermatologist and Clinical Investigator at the SKiN Centre for Dermatology in Peterborough, Ontario, Canada. She is an Assistant Professor at Queen's University and a consultant Physician at the Peterborough Regional Health Centre. She practices with a focus on inflammatory diseases of the skin.
Author disclosures
M. Gooderham has received honoraria, grants, and/or research funding as a speaker, investigatory, advisory board member, data safety monitoring board member, and/or consultant for: AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, Kyowa Kirin, Leo Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Valeant /Bausch
